ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements • Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings •...

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I...

K92 Mining Schedules 2024 Second Quarter Financial Results Conference Call K92 Mining Schedules Second Quarter Financial Results Conference Call